At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 35 enrolled

Drug / intervention

Floxuridine (FUDR) +6 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03693807

NCT03693807Phase 2Completed

Compare CT.gov

A Pilot Protocol Evaluating Safety of Using the Medtronic Pump and Codman Catheter for the Delivery of Hepatic Arterial Infusion (HAI) Chemotherapy in Patients With Colorectal Carcinoma or Cholangiocarcinoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Oct 3, 2018·Updated Feb 6, 2026

In Brief

A Phase 2 clinical trial evaluating Medtronic pump and Codman catheter, Floxuridine (FUDR), and 5 other interventions for Colorectal Cancer and Cholangiocarcinoma. Completed, enrolled 35 participants across 7 sites.

Detailed Summary

This study is being done to answer the following question: Is the combination of the Medtronic pump and the Codman catheter device a safe alternative to the C3000 Codman pump for delivering chemotherapy directly into the liver of patients with metastatic colorectal cancer or cholangiocarcinoma?

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsColorectal Cancer, Cholangiocarcinoma

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

20192020202120222023202420252026

First PostedOct 2018

Enrollment StartOct 2018

Primary CompletionJun 2024

TodayJul 2026

First PostedOct 3, 2018

Enrollment StartOct 18, 2018

Primary CompletionJun 27, 2024

TodayJul 2, 2026

Enrollment to primary: 5.7 yearsPosted 7.7 years ago

Interventions

Medtronic pump and Codman catheterdevice

All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.

Floxuridine (FUDR)drug